PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study
Descrição
PDF) Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
PDF) Ranibizumab for the treatment of wet AMD: A summary of real-world studies
PDF) Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
PDF) Rate of vision loss in neovascular age-related macular degeneration explored
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study, BMC Ophthalmology
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study, BMC Ophthalmology
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect
High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial
de
por adulto (o preço varia de acordo com o tamanho do grupo)
